Evidence and analysis
Research evidence pack
Source-backed valuation visuals
2. Company Fundamentals
2.3 Management
| Role | Metric |
|---|---|
| Consensus Rating | N/A |
2.4 Return
| Metric | Value |
|---|---|
| Expected Return (Ann.)* | 1498.34% |
| Risk / Std Dev (Ann.)* | 157.36% |
| 1-Year Price Return* | 438.89% |
Latest Market Data (as of 2026-08-14, Hong Kong time):
| Metric | Value |
|---|---|
| Last Price | HK$6.79 |
| 52-Week Range | HK$0.75 – HK$10.2 |
| Observation Count | 245 trading days |
The return and risk statistics use daily adjusted closes from the retrieved one-year price series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.
DuPont Model Analysis
The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:
ROE = Net Margin × Asset Turnover × Equity Multiplier
The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in HK$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.
| DuPont component | Calculation | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | Reported revenue | HK$112.94M | HK$173.33M |
| Net income | Reported net income | HK$69.10M | HK$114.62M |
| Total assets | Year-end reported balance | HK$174.36M | HK$80.87M |
| Shareholders’ equity | Year-end reported balance | HK$79.69M | HK$-228.70M |
| Net margin | Net income ÷ revenue | 61.18% | 66.13% |
| Asset turnover | Revenue ÷ total assets | 0.6478x | 2.1434x |
| Equity multiplier | Total assets ÷ shareholders’ equity | 2.1879x | -0.3536x |
| ROE | Net margin × asset turnover × equity multiplier | 86.71% | -50.12% |
Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.
2.5 FCFF DCF Valuation
FCFF DCF exception: Reported working-capital, D&A, or capex ratio appears anomalous and requires primary-filing review. This post deliberately does not publish a mechanical enterprise value or implied per-share value on an unsuitable basis.
| Available valuation input | Value |
|---|---|
| Last market price | HK$6.30 |
| Market capitalisation | HK$3.28B |
| Revenue | HK$112.94M |
| EBIT | HK$72.83M |
| Reported free cash flow | -HK$75.73M |
| FCF yield | -2.31% |
| Net debt / EBITDA | -0.38x |
2.6 Investor-Style Research Screen
| Educational screen | Result |
|---|---|
| Buffett-inspired cash-quality checks | not rated — FCFF DCF suitability or data-integrity condition not met |
| Lynch-inspired balance-and-growth checks | not rated — FCFF DCF suitability or data-integrity condition not met |
Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 16:12:38.783654 UTC; latest reported fiscal period: 2025-12-31 00:00:00. Financial institutions and REITs require sector-specific methods rather than a mechanical FCFF DCF. This is research and analysis only, not personalized financial advice.
2.7 Quantitative Factor Diagnostics
Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.
| Estimation input | Value |
|---|---|
| Regional factor set | Asia Pacific ex Japan |
| Factor-return currency | USD |
| Issuer-return basis | USD adjusted total return |
| Estimation window | 2025-08-20 to 2026-06-30 |
| Aligned daily observations | 210 |
| Minimum observation requirement | 120 |
| Currency conversion for HK listings | HKD adjusted close divided by daily USD/HKD close before simple daily return calculation |
Fama–French Three-Factor and Five-Factor Results
| Diagnostic | FF3 | FF5 |
|---|---|---|
| Annualised alpha | 4,971.92% | 5,086.28% |
| Adjusted R² | 0.02 | 0.02 |
| Annualised residual volatility | 163.70% | 163.27% |
| Factor loading (t-statistic) | FF3 | FF5 |
|---|---|---|
| Market excess return (Mkt-RF) | -1.31 (-1.41) | -1.09 (-1.08) |
| Size (SMB) | 2.27 (1.66) | 2.68 (1.56) |
| Value (HML) | -2.37 (-1.83) | -3.01 (-2.09) |
| Profitability (RMW) | NM | -1.47 (-0.80) |
| Investment (CMA) | NM | 1.28 (0.62) |